Goldman Sachs initiates coverage on Erasca: focusing on the differentiated potential of ERAS-0015 in large RAS-mutant tumor opportunities

Overview

This report initiates coverage on Erasca Inc. Erasca is a clinical-stage precision oncology company focused on cancers driven by the RAS/MAPK pathway, with key pipeline assets including ERAS-0015 and ERAS-4001. The report believes RAS-mutant cancers account for about one-third of human cancers and represent significant unmet need in PDAC, NSCLC, and CRC. If ERAS-0015 can differentiate on efficacy, tolerability, or launch timing, it could gain meaningful market share.

Core views

The core view is that although ERAS-0015 is still early stage, clinical data have already shown it to be at least competitive with RVMD daraxonrasib: a higher unconfirmed response rate in NSCLC, preliminary comparable efficacy in PDAC, and numerically lower rash and gastrointestinal toxicity so far. The report considers the tolerability difference especially important because it may improve the feasibility of combining ERAS-0015 with PDAC chemotherapy, CRC anti-EGFR antibodies, and other targeted or immunotherapies. Monotherapy expansion and combination dose-escalation data in 1H27 will determine whether this asset truly achieves clinical differentiation.

Analysis framework

The report uses a combination of company pipeline review, disease epidemiology, competitor comparison, KOL views, early clinical data interpretation, and sales potential modeling. It focuses on comparing ERAS-0015 with pan-RAS competitors such as daraxonrasib in mechanism, efficacy, tolerability, clinical development pace, and indication pathway differences, while assessing the commercial opportunity across the three major RAS-mutant cancer types: NSCLC, PDAC, and CRC.

Methodology notes

• biotech_equity_researchclinical_pipeline_assessment

  clinical pipeline assessment

  Assesses the risk-reward of core assets at early-stage biotech companies through differences in mechanism, early efficacy, safety, PK, recommended expansion dose, indication selection, and key catalysts.

• oncology_market_analysisunmet_need_and_competitive_positioning

  unmet need and competitive positioning

  Combines patient scale in RAS-mutant cancers, limitations of current standard treatments, competitor data, and KOL feedback to assess whether ERAS-0015 may differentiate on efficacy or tolerability.

• Valuation methodsrisk_adjusted_pipeline_model

  risk-adjusted pipeline model

  The report models peak unadjusted sales for ERAS-0015 in 1L PDAC, 1L/2L non-G12C NSCLC, and 2L CRC, while also conducting scenario sensitivity analysis on probability, discount rate, and terminal growth rate.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• ERAS.US

  covered company stock

  Strengths

  Owns two clinical-stage RAS/KRAS-related assets, ERAS-0015 and ERAS-4001, is positioned relatively ahead among pan-RAS competitors, and cash is expected to support operations through 2H28.

  Weaknesses

  The core asset is still early stage, differentiation in durability of efficacy and safety has not been fully validated, and there is currently no commercial revenue.

  Comparison

  The report primarily compares ERAS-0015 with RVMD's daraxonrasib and believes it may be behind RVMD but ahead of most other pan-RAS competitors.

  Risks

  Immature clinical data, uncertainty in cross-trial comparisons, intensifying competition in RAS-mutant cancers, and the possibility that toxicity or efficacy in combination therapy may fall short of expectations.

• ERAS-0015

  core clinical asset

  Strengths

  An oral pan-RAS molecular glue with early data showing a high uORR in NSCLC, comparable efficacy in PDAC, and potentially better rash and gastrointestinal tolerability.

  Weaknesses

  The data sample is still small, some responses remain unconfirmed, and durability is not yet mature.

  Comparison

  Versus daraxonrasib, the report focuses on whether it can differentiate in tolerability, NSCLC efficacy, or the combination-therapy pathway.

  Risks

  If the 1H27 update fails to confirm separation in efficacy and safety, the best-in-class narrative may weaken.

• ERAS-4001

  second clinical asset

  Strengths

  A pan-KRAS inhibitor that is designed to spare HRAS/NRAS, potentially providing a different safety window.

  Weaknesses

  The report does not currently include it in the model, and clinical data are still pending disclosure in 2H26.

  Comparison

  Compared with pan-RAS and mutation-specific KRAS assets, the market will focus on the trade-off between safety and early response rate.

  Risks

  If HRAS/NRAS sparing leads to tumor escape or insufficient efficacy, the asset's value may be limited.

Key data

• current price$18.53Disclosed in the front-page table; target price and upside were not provided.
• market capitalization$5.6bnDisclosed in the KeyData table.
• enterprise value$5.3bnDisclosed in the KeyData table.
• 3-month average daily trading value$101.2mnDisclosed in the KeyData table.
• ERAS-0015 peak unadjusted sales model$8.7BCovers RAS-mutant 1L PDAC, 1L/2L non-G12C NSCLC, and 2L CRC.
• ERAS-0015 active dose range16-32mg QDPharmacologically active dose range supported by PK and ctDNA data.
• preliminary NSCLC efficacy62% overall uORR at PADOverall unconfirmed objective response rate was 62% among 37 patients at 16 to 32mg QD.
• PDAC China data36% uORR at RDE; 41% in 2LFor 2L+ KRAS G12X PDAC, uORR was 36% at the RDE dose, and 41% in 2L alone.
• cash runwayapproximately $409M, supports operations through 2H28Cash, cash equivalents, and marketable securities as of March 31, 2026.
• ERAS-4001 catalystpreliminary Ph1 data in 2H26Expected to disclose safety, tolerability, PK, and early efficacy data.

Impact & implications

If ERAS-0015 confirms durable efficacy and maintains better tolerability in its 1H27 data, its investment implication would upgrade from an 'early competitive asset' to a 'core platform asset capable of gaining differentiated share in the large pan-RAS market.' If the data are only similar to daraxonrasib, the report still believes second entrants in oncology markets can gain share through market size and development learning; however, if efficacy, tolerability, or combination feasibility fail to separate, valuation and the development path would face downside risk.

Risks

• ERAS-0015 clinical data are still early, with limited sample size and some responses unconfirmed.
• Cross-trial comparisons are uncertain, especially comparisons with RVMD daraxonrasib on efficacy and safety.
• Durability of efficacy in PDAC, NSCLC, and CRC indications is not yet mature, and further follow-up may change the conclusions.
• The number of competitors in the pan-RAS and pan-KRAS fields is increasing, and the launch timing and differentiation window may narrow.
• The combination-therapy pathway may be affected by gastrointestinal or skin toxicity, or dose limitations.
• The company remains an early-stage biotech with zero revenue and high R&D spending, and funding and financing conditions may affect development pace.

What to watch

• 1H27 ERAS-0015 monotherapy expansion data, especially durability of response in NSCLC.
• 1H27 ERAS-0015 combination dose-escalation data, especially safety when combined with chemotherapy, EGFR antibodies, or immunotherapy.
• Whether response rates improve after longer follow-up in the U.S. PDAC cohort.
• Whether rash, gastrointestinal events, grade 3+ rash, and discontinuation rates continue to be better than competitors.
• 2H26 ERAS-4001 Ph1 safety, PK, and early efficacy data.
• Whether ERAS-0015 in NSCLC could support an accelerated approval pathway.